Copper-Catalyzed Cross-Coupling of Alkyl Grignard Reagents and Propargylic Ammonium Salts: Stereospecific Synthesis of Allenes

Manuel Guisán-Ceinos, Víctor Martín-Heras, Rita Soler-Yanes, Diego J. Cárdenas* and Mariola Tortosa*

Departamento de Química Orgánica (Módulo-01), Facultad de Ciencias, Universidad Autónoma de Madrid. 28049-Madrid, Spain

Supporting Information

Table of Contents

	1	GENERAL EXPERIMENTAL DETAILS	2
	2	OPTIMIZATION DETAILS	.3
	3	PREPARATION OF (4-PHENYLBUTYL)MAGNESIUM BROMIDE SOLUTION	.5
GRI	4 GNAR	COPPER-CATALYZED REACTION OF PROPARGYLIC AMMONIUM TRIFLATES WITH ALKYL D REAGENTS	.6
	5	ASSIGNMENT OF ABSOLUTE CONFIGURATION	18
	6	NMR SPECTRA	19
	7	SFC CROMATOGRAMS	37
	8	REFERENCES	48

1 GENERAL EXPERIMENTAL DETAILS

Tetrahydrofuran and dichloromethane were purified by passing through a Pure Solv[™] column drying system from Innovative Technology, Inc. Additionally, Tetrahydrofuran and dichloromethane were degassed passing Ar through them for 15 min. Diethyl ether was dried using activated 4Å molecular sieves and stored under argon. Unless indicated otherwise, all reactions were conducted under an argon atmosphere using flame-dried glassware with standard vacuum-line techniques. NMR spectra were acquired on a Bruker 300 spectrometer, running at 300, and 75 MHz for ¹H and ¹³C respectively. Chemical shifts (δ) are reported in ppm relative to residual solvent signals (CDCl₃, 7.26 ppm for ¹H NMR and 77.2 ppm for ¹³C NMR respectively). ¹³C NMR spectra were acquired on a broad band decoupled mode. The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sex (sextet), sept (septuplet), m (multiplet), br (broad). Analytical thin layer chromatography (TLC) was performed using pre-coated aluminium-backed plates (Merck Kieselgel 60 F254) and visualized by ultraviolet irradiation or phosphomolybdic acid dip or potassium permanganate dip. Purification of reaction mixtures was carried out by flash chromatography (FC) using silica gel Merck-60. Optical rotations were measured on a Perkin-Elmer 241 polarimeter. The enantiomeric ratio (er) of the products was determined by stationary phase SFC, HPLC or GC using chiral columns. Mass Spectrometry (MS) and High-Resolution Mass Spectrometry (HRMS) were registered in a spectrometer GCT Agilent Technologies 6890N using Electronic Impact (E.I.) techniques at 70 eV, Fast Atom Bombardment and electrospray (ESI⁺ or ESI⁻).

All ligands and $[Cu(CH_3CN)_4]PF_6$ were acquired from commercial sources and were used without further purification. Grignard reagents were acquired from commercial sources and were tritrated prior to use.¹ Propargylic ammonium salts were prepared following reported procedures and the enantiomeric ratios are specified in scheme 1.²



Scheme 1: Enantiomeric ratios of ammonium salts.

2 OPTIMIZATION DETAILS

General procedure for the copper-catalyzed reaction of propargylic ammonium salts and Grignard reagents

An oven-dried vial was charged with Cu(I), the ligand and the corresponding ammonium salt (0.2 mmol) and sealed with a septum. The vial was connected to an argon-vacuum line, evacuated and backfilled with argon (x3). CH₂Cl₂ (2 mL) was added and the mixture was stirred for 5 min at room temperature. The reaction mixture was cooled to -40 °C and a (1,3-Dioxan-2-ylethyl)magnesium bromide solution in THF (0.3 M, 0.22 mmol) was added dropwise. The mixture was stirred at -40 °C for 5 minutes. Water (0.1 mL) was added and the solution was filtered through a short pad of MgSO₄ and rinsed with CH₂Cl₂. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography using *n*-hexane as eluent. The enantiomeric ratio was determined by SFC using Chiralpak-ID column [CO₂/MeOH (98:2)], 1.0 mL/min, τ_{maior} = 10.9 min, τ_{minor} = 12.4 min.



Γable S1: Influence of the	e copper and temp	perature.
----------------------------	-------------------	-----------

Entry	[Cu] (mol%)	L (mol%)	Т (°с)	Yield ^b (%)	er ^c
2	Cu(CH,CN),PF, (5)	Sphos (6)	-40	90	98.2
2	Cu(CH CN) PF (5)	Sphos (6)	0	76	95:5
2	Cu(CH ₃ CN) ₄ PF ₆ (5)	Sphos (6)	rt	77	95:5
2	-	-	rt	24	78:22

^aReaction conditions: following general procedure. ^bIsolated yield after column chromatography. ^cDetermined by chiral SFC.

Table S2: Influence of the nature of the counterion.^a



^aReaction conditions: following general procedure. ^bIsolated yield after column chromatography. ^cDetermined by ¹H-NMR. ^dDetermined by chiral SFC.



Table S3: Influence of the nature of the leaving group.^a

^aReaction conditions: following general procedure. ^bYield was determined by isolation. ^cDetermined by ¹H-NMR. ^dDetermined by chiral SFC.

3 SYNTHESIS OF STARTING MATERIALS

3.1 Synthesis of (–)-(S)-6-phenylhex-3-yn-2-ol, (S)-SI-1z

он (*S*)-SI-1z To an oven-dried round bottom flask was added (\pm) -6-phenylhex-3-yn-2-ol (1.90 g, 10.9 mmol), molecular sieves (0.95 g) and Amano Lipase from Pseudomonas fluorescens (0.95 g). The flask was connected to an argon-vacuum line, evacuated and backfilled with argon (x3). *n*-Hexane (100 mL) and Vinyl acetate (2.7 mL, 33 mmol) were added and the reaction mixture was stirred at

room temperature for 2 h. After completion (checked by chiral HPLC) the reaction was filtered and the solvent was removed under reduced pressure. Longer reaction times, results in complete acetylation of the alcohol. Compound **(S)-SI-1z** (853 mg, 4.9 mmol) was obtained in 45% yield as a yellowish oil after flash column chromatography (Cy/EtOAc, 90/10).

Compound **(S)-SI-1s** was obtained in 99:1 enantiomeric ratio determined by HPLC using Chiralpak-IBN column [CO₂/MeOH (95:5)], 1.0 mL/min, τ_{major} = 11.2 min, τ_{minor} = 6.4 min. ¹H NMR, ¹³C NMR and MS data were consistent with literature values. ³ [α]²⁰_D= -33.1 (*c* = 1.0, CHCl₃).

3.2 Synthesis of (+)-*N*,*N*-Dimethyl-6-phenylhex-3-yn-2-amine, SI-2z.



To a solution of **(S)-SI-1z** (800 mg, 4.6 mmol) and triethylamine (3.2 mL, 23 mmol) in THF (12 mL) was added methanesulfonyl chloride (708 μ L, 9.2 mmol) at 0 °C. The reaction was stirred for 1 h at room temperature and then, a solution of dimethylamine (12 mL, 2 M in THF, 23 mmol) was added to the mixture. The temperature was raised to 50 °C and the reaction mixture was stirred for 16 h. The reaction mixture was filtered through a short pad of Celite® and rinsed with Et₂O. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography (From Cy/EtOAc 2:1 to EtOAc gradient). Compound **(***R***)-SI-2z** (845 mg, 4.2 mmol) was obtained in 91% yield as a yellowish oil.

¹H NMR, ¹³C NMR and MS data were consistent with literature values. ² $[\alpha]^{20}_{D}$ = +18.4 (*c* = 1.0, CHCl₃).

3.3 Synthesis of (+)-(*R*)-*N*,*N*,*N*-trimethyl-6-phenylhex-3-yn-2-aminium trifluoromethanesulfonate, (*R*)-1z.



To a solution of (*R*)-SI-2z (800 mg, 4 mmol) in Et₂O (8 mL) was added methyl trifluoromethanesulfonate (540 μ L, 4.77 mmol) at 0 °C. The reaction was stirred for 1 h at 0 °C and a white solid precipitated. The mixture was filtered through a fritted funnel and was washed with cold Et₂O. The white solid was dried under vacuum for 16 h. Compound (*R*)-SI-2z (1.35 g, 3.75 mmol) was obtained in 93% yield as a white solid.

¹H NMR, ¹³C NMR and MS data were consistent with literature values. ² $[\alpha]^{20}_{D}$ = +7.5 (*c* = 1.0, CHCl₃).

4 PREPARATION OF (4-PHENYLBUTYL)MAGNESIUM BROMIDE SOLUTION

An oven-dried flask was charged with magnesium (72 mg, 3 mmol, 1 equiv) and a couple of crystals of iodine under Ar atmosphere. Dry THF (6 mL) was added and the mixture was stirred for 2 min. (4-bromobutyl)benzene was added dropwise to the mixture observing a gentle reflux. The mixture was stirred for 2h and then, it was allowed to rest for 24 h. The supernatant was filtered and the solution was tritrated to determine its concentration (0,43M).¹

5 COPPER-CATALYZED REACTION OF PROPARGYLIC AMMONIUM TRIFLATES WITH ALKYL GRIGNARD REAGENTS.

General procedure for the reactions of (\pm) propargylic ammonium (1) salts with alkylmagnesium halides.

An oven-dried vial was charged with $[Cu(CH_3CN)_4]PF_6$ (3.8 mg, 0.01 mmol) and the correspondent ammonium salt (0.2 mmol) and sealed with a septum. The vial was connected to an argon-vacuum line, evacuated and backfilled with argon (x3). DCM (2 mL) was added and the mixture was stirred for 5 min at room temperature. The reaction

mixture was cooled to -40 °C and the alkyl magnesium bromide solution in THF (0.22 mmol) was added dropwise and the mixture was stirred at -40 °C for 5 minutes. After total conversion observed by TLC (5 minutes), water (0.1 mL) was added and the solution was filtered through a short pad of MgSO₄ and rinsed with DCM. Solvent was removed under reduced pressure and the crude product was purified by flash column chromatography.

General procedure for the reactions of enantiopure propargylic ammonium (1) salts with alkylmagnesium halides.

An oven-dried vial was charged with $[Cu(CH_3CN)_4]PF_6$ (3.8 mg, 0.01 mmol), Sphos (4.9 mg, 0.012 mmol) and the correspondent ammonium salt (0.2 mmol) and sealed with a septum. The vial was connected to an argon-vacuum line, evacuated and backfilled with argon (x3). DCM (2 mL) was added and the mixture was stirred for 5 min at room temperature. The reaction mixture was cooled to -40 °C and the alkyl magnesium bromide solution in THF (0.22 mmol) was added dropwise and the mixture was stirred at -40 °C for 5 minutes. After total conversion observed by TLC (5 minutes), water (0.1 mL) was added and the solution was filtered through a short pad of MgSO₄ and rinsed with DCM. Solvent was removed under reduced pressure and the crude product was purified by flash column chromatography.

(--)-(*R*)-2-(3-phenylhexa-3,4-dien-1-yl)-1,3-dioxane (2a).



From (*R*)-1a (67 mg, 0.2 mmol) and (1,3-Dioxan-2ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2a (44 mg, 0.18 mmol) was obtained in 90% yield as a pale yellow oil, after purification by flash column chromatography (cyclohexane/EtOAc 95:5). From (±)-1a, following the same procedure without Sphos, compound (±)-2a (42 mg, 0.17 mmol) was obtained in 86% yield.

(*R*)-2a ¹H NMR, ¹³C NMR and MS data for (±)-2a were consistent with literature values.⁴ Compound (*R*)-2a was obtained in 98:2 enantiomeric ratio determined by SFC using Chiralpak-ID column [CO₂/MeOH (98:2)], 1.0 mL/min, τ_{major} = 12.9 min, τ_{minor} = 14.4 min. [α]²⁵_D= -64.1 (*c* = 1.0, CHCl₃).

The reaction was also carried out in gram scale, from (*R*)-1a (1.0 g, 2.96 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (3.3 mmol) affording compound (*R*)-2a (614 mg, 2.47 mmol) in 85% yield as a yellow oil and enantiomeric ratio of 98:2.

(-)-(*R*)-2-(3-(3-methoxyphenyl)hexa-3,4-dien-1-yl)-1,3-dioxane (2b).



From (*R*)-1b (74 mg, 0.2 mmol) and (1,3-dioxan-2ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2b (51 mg, 0.19 mmol) was obtained in 93% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3). From (±)-1b, following the same procedure without SPhos, compound (±)-2b (51 mg, 0.19 mmol) was obtained in 93% yield.

(*R*)-2b

¹H NMR, ¹³C NMR and MS data for (±)-2b were consistent with literature values.⁴ Compound (*R*)-2a was obtained in 98:2 enantiomeric ratio determined by SFC using Chiralpak-IA column [CO₂/MeOH (99:1)], 1.0 mL/min, τ_{major} = 25.5 min, τ_{minor} = 27.3 min. [α]²⁵_D= -66.7 (*c* = 1.0, CHCl₃).

(±)-2-(3-(4-Methoxyphenyl)hexa-3,4-dien-1-yl)-1,3-dioxane (2c).



From **1c** (74 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol), following the general procedure described above, compound **2c** (33 mg, 0.12 mmol) was obtained in 60% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3).

¹**H NMR** (300 MHz, CDCl₃) δ 7.35 – 7.29 (m, 2H), 6.88 – 6.82 (m, 2H), 5.53 – 5.41 (m, 1H), 4.62 (t, *J* = 5.2 Hz, 1H), 4.19 – 4.06 (m, 2H), 3.81 – 3.71 (m, 2H), 3.80 (s, 3H), 2.51 – 2.42 (m, 2H), 2.16 –

2.03 (m, 1H), 1.89 – 1.80 (m, 2H), 1.74 (d, J = 7.0 Hz, 3H), 1.38 – 1.31 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 204.0, 158.5, 129.8, 127.2, 113.9, 104.3, 102.1, 89.7, 67.1, 55.4, 33.8, 26.0, 24.4, 14.7. **HRMS-(EI)** calculated for C₁₇H₂₁O₃ [M]⁺: 274.1491; Found 274.1495.

(±)-2-(3-(4-chlorophenyl)hexa-3,4-dien-1-yl)-1,3-dioxane (2d).



From **1d** (74 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2d** (50 mg, 0.18 mmol) was obtained in 90% yield as a pale yellow oil, after purification by flash column chromatography (cyclohexane/Et₂O 95:5). ¹H NMR, ¹³C NMR and MS data were consistent with literature values.⁴

(-)-(*R*)-2-(3-(4-fluorophenyl)hexa-3,4-dien-1-yl)-1,3-dioxane (2e).



From (*R*)-1e (71 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2e (50 mg, 0.19 mmol) was obtained in 95% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3). From (±)-1e, following the same procedure without SPhos, compound (±)-2e (44 mg, 0.17 mmol) was obtained in 84% yield.

Compound (*R*)-2e was obtained in 97:3 enantiomeric ratio determined by SFC using Chiralpak-ID column [CO₂/MeOH (99:1)],

1.0 mL/min, τ_{major} = 18.7 min, τ_{minor} = 20.8 min. ¹H NMR (300 MHz, CDCl₃) δ 7.40 – 7.30 (m, 2H), 7.03 – 6.92 (m, 2H), 5.49 (qt, *J* = 6.9, 3.2 Hz, 1H), 4.62 (t, *J* = 5.1 Hz, 1H), 4.20 – 4.04 (m, 2H), 3.86 – 3.69 (m, 2H), 2.56 – 2.35 (m, 2H), 2.19 – 2.00 (m, 1H), 1.88 – 1.80 (m, 2H), 1.75 (d, *J* = 7.0 Hz, 3H), 1.40 – 1.30 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 204.3 (d, *J*_{C-F} = 2.0 Hz), 161.8 (d, *J*_{C-F} = 245.4 Hz), 133.4 (d, *J*_{C-F} = 3.2 Hz), 127.6 (d, *J*_{C-F} = 7.9 Hz), 115.2 (d, *J*_{C-F} = 21.4 Hz), 140.0, 101.9, 90.1, 67.1, 33.7, 26.0, 24.4, 14.5. HRMS-(EI) calculated for C₁₆H₁₈FO₂ [M-H]⁺: 261.1291; Found: 261.0887. [α]²⁵_D= -68.1 (*c* = 1.0, CHCl₃).

(±)-2-(3-(3-Bromophenyl)hexa-3,4-dien-1-yl)-1,3-dioxane (2f).



From **1f** (83 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2f** (58 mg, 0.18 mmol) was obtained in 90% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 95:5).

¹**H NMR** (300 MHz, CDCl₃) δ 7.52 (t, J = 1.9 Hz, 1H), 7.30 (ddt, J = 8.0, 5.1, 1.3 Hz, 2H), 7.15 (t, J = 7.9 Hz, 1H), 5.53 (qt, J = 7.0, 3.3 Hz, 1H), 4.61 (t, J = 5.2 Hz, 1H), 4.19 – 4.07 (m, 2H), 3.84 –

3.71 (m, 2H), 2.55 – 2.36 (m, 2H), 2.19 – 2.02 (m, 1H), 1.88 – 1.79 (m, 2H), 1.76 (d, J = 7.0 Hz, 3H), 1.40 – 1.30 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 204.7, 140.0, 129.8, 129.4, 129.1, 124.6, 122.7, 104.0, 102.0, 90.5, 67.1, 33.7, 26.0, 24.0, 14.4. **HRMS** (EI) calculated for C₁₆H₁₉BrO₂ [M]⁺: 322.0568; Found: 322.0552.

(±)-Methyl 4-(1-(1,3-dioxan-2-yl)hexa-3,4-dien-3-yl)benzoate (2g).



From **1g** (79 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2g** (54 mg, 0.17 mmol) was obtained in 89% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 90:10). ¹H NMR, ¹³C NMR and MS data were consistent with literature values.⁴

(±)-Methyl 2-(1-(1,3-dioxan-2-yl)hexa-3,4-dien-3-yl)benzoate (2h).



From **1h** (79 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2h** (30 mg, 0.10 mmol) was obtained in 50% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 90:10).

¹**H NMR** (300 MHz, CDCl₃) δ 7.67 (dd, J = 7.7, 1.5 Hz, 1H), 7.45 – 7.37 (m, 1H), 7.33 – 7.26 (m, 2H), 5.25 (qt, J = 6.8, 3.2 Hz,

1H), 4.61 (t, J = 5.2 Hz, 1H), 4.14 – 4.05 (m, 2H), 3.86 (s, 3H), 3.81 – 3.69 (m, 2H), 2.46 – 2.35 (m, 2H), 2.14 – 2.00 (m, 1H), 1.85 – 1.77 (m, 2H), 1.66 (d, J = 7.0 Hz, 3H), 1.37 – 1.28 (m, 1H). ¹³**C** NMR (75 MHz, CDCl₃) δ 203.2, 168.8, 139.5, 131.1, 130.8, 129.7, 129.28, 126.6, 104.5, 101.8, 87.8, 66.9, 52.0, 33.6, 27.7, 25.9, 14.3. HRMS (EI) calculated for C₁₈H₂₂O₄ [M]⁺: 302.1518; Found: 302.1509.

(±)-4-(1-(1,3-Dioxan-2-yl)hexa-3,4-dien-3-yl)benzonitrile (2i).



From **1i** (72 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2i** (45 mg, 0.17 mmol) was obtained in 84% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 90:10). ¹H NMR, ¹³C NMR and MS data were consistent with literature values.⁴

(--)-(*R*)-3-(1-(1,3-dioxan-2-yl)hexa-3,4-dien-3-yl)benzonitrile (2j).



From (*R*)-1j (72 mg, 0.2 mmol) and (1,3-dioxan-2ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2j (50 mg, 0.19 mmol) was obtained in 93% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 90:10). From (±)-1j, following the same procedure, compound (±)-2j (49 mg, 0.18 mmol) was obtained in 91% yield.

Compound (*R*)-2j was obtained in 95:5 enantiomeric ratio determined by SFC using Chiralpak-IB column [CO₂/MeOH (99:1)], 1.0 mL/min, τ_{major} = 28.3 min, τ_{minor} = 26.6 min. ¹H NMR (300 MHz, CDCl₃) δ 7.65 (t, *J* = 1.8 Hz, 1H), 7.59 (dt, *J* = 7.7, 1.7 Hz, 1H), 7.46 – 7.33 (m, 2H), 5.57 (qt, *J* = 7.0, 3.3 Hz, 1H), 4.61 (t, *J* = 5.1 Hz, 1H), 4.16 – 4.06 (m, 2H), 3.83 – 3.69 (m, 2H), 2.51 – 2.38 (m, 2H), 2.17 – 1.99 (m, 1H), 1.87 – 1.77 (m, 2H), 1.76 (d, J = 7.1 Hz, 3H), 1.39 – 1.30 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 204.8, 139.0, 130.1, 129.8, 129.6, 129.1, 119.2, 112.4, 103.5, 101.6, 91.1, 67.0, 33.5, 25.9, 23.8, 14.2. HRMS (ESI) calculated for C₁₇H₁₉NNaO₂ [M+Na]⁺: 292.1313; Found: 292.1318. [α]²⁵_D= -89.3 (*c* = 1.0, CHCl₃).

(±)-1-(4-(1-(1,3-Dioxan-2-yl)hexa-3,4-dien-3-yl)phenyl)ethanone (2k).



From **1k** (76 mg, 0.2 mmol) and (1,3-dioxan-2ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above (catalytic charge was changed to 0.02 mmol), compound **2k** (23 mg, 0.08 mmol) was obtained in 40% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 80:20). ¹H NMR, ¹³C NMR and MS data were consistent with literature values.⁴

(±)-2-(3-(4-(Trifluoromethyl)phenyl)hexa-3,4-dien-1-yl)-1,3-dioxane (2l).



From **1I** (81 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2I** (58 mg, 0.19 mmol) was obtained in 93% yield as a pale yellow oil, after purification by flash column chromatography (hexane/AcOEt 95:5). ¹H NMR, ¹³C NMR and MS data were consistent with literature values.⁴

(±)-2-(3-(Thiophen-2-yl)hexa-3,4-dien-1-yl)-1,3-dioxane (2m).



From **1m** (69 mg, 0.2 mmol) and (1,3-dioxan-2ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound **2m** (40 mg, 0.16 mmol) was obtained in 80% yield as a pale yellow oil, after purification by flash column chromatography (cyclohexane/EtOAc 95:5).

¹**H NMR** (300 MHz, CDCl₃) δ 7.13 (dd, J = 5.0, 1.4 Hz, 1H), 7.00 – 6.90 (m, 2H), 5.51 (qt, J = 6.9, 3.2 Hz, 1H), 4.62 (t, J = 5.2 Hz, 1H), 4.18 – 4.09 (m, 2H), 3.83 – 3.73 (m, 2H), 2.54 – 2.44 (m, 2H), 2.16 –

2.03 (m, 1H), 1.91 – 1.82 (m, 2H), 1.72 (d, J = 3.3 Hz, 3H), 1.40 – 1.31 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 203.4, 143.0, 127.4, 124.1, 122.7, 101.9, 100.8, 90.6, 67.1, 33.6, 26.0, 25.5, 14.6. **HRMS** (EI) calculated for C₁₄H₁₇O₂S [M-H]⁺: 249.0949; Found: 249.0553.

(±)-2-(3-Phenethylhexa-3,4-dien-1-yl)-1,3-dioxane (2n).



From **1n** (73 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above (temperature was changed to rt), compound **2n** (33 mg, 0.12 mmol) was obtained in 61% yield as a pale yellow oil, after purification by flash column chromatography (cyclohexane/EtOAc 95:5).

¹**H NMR** (300 MHz, CDCl₃) δ 7.29 – 7.24 (m, 2H), 7.22 – 7.13 (m, 3H), 5.08 (qt, *J* = 7.8, 3.4, 1H), 4.54 (t, *J* = 5.2 Hz, 1H), 4.16 –

4.05 (m, 2H), 3.82 – 3.68 (m, 2H), 2.77 – 2.66 (m, 2H), 2.29 – 2.18 (m, 2H), 2.15 – 1.99 (m, 3H), 1.79 – 1.68 (m, 2H), 1.55 (d, J = 7.1 Hz, 3H), 1.39 – 1.29 (m, 1H). ¹³**C NMR** (75 MHz, CDCl₃) δ 201.7, 142.5, 128.5, 128.31, 125.8, 102.8, 102.1, 87.9, 67.1, 34.7, 34.2, 33.4, 27.0, 26.0, 15.0. **HRMS** (ESI) calculated for C₁₈H₂₄NaO₂ [M+Na]⁺: 295.1674; Found: 295.1665.

(--)-(*R*)-2-(3-Phenylundeca-3,4-dien-1-yl)-1,3-dioxane (20).



From (*R*)-1o (82 mg, 0.2 mmol) and (1,3-dioxan-2-ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2o (48 mg, 0.15 mmol) was obtained in 76% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 95:5). From (±)-1o, following the same procedure without SPhos, compound (±)-2o (51 mg, 0.16 mmol) was obtained in 81% yield.

Compound (*R*)-20 was obtained in 98:2 enantiomeric ratio determined by SFC using Chiralpak-IB column [CO₂/MeOH (99:1)], 1.0 mL/min, τ_{major} = 28.3 min, τ_{minor} = 27.7

min. ¹H NMR (300 MHz, CDCl₃) δ 7.45 – 7.38 (m, 2H), 7.33 – 7.27 (m, 2H), 7.21 – 7.13 (m, 1H), 5.53 (tt, *J* = 6.6, 3.3 Hz, 1H), 4.63 (t, *J* = 5.2 Hz, 1H), 4.20 – 4.05 (m, 2H), 3.83 – 3.68 (m, 2H), 2.57 – 2.45 (m, 2H), 2.16 – 2.06 (m, 3H), 1.92 – 1.81 (m, 2H), 1.56 – 1.21 (m, 10H), 0.96 – 0.82 (m, 3H). ¹³C NMR (76 MHz, CDCl₃) δ 203.6, 137.6, 128.4, 126.5, 126.0, 105.2, 102.1, 95.5, 67.1, 33.8, 31.8, 29.4, 29.3, 29.1, 26.0, 24.2, 22.8, 14.2. HRMS (EI) calculated for C₂₁H₃₀O₂ [M]⁺: 314.2246; Found: 314.2223. [α]²⁵_D= -78.2 (*c* = 1.0, CHCl₃).

(±)-2-(7-(Methylthio)-3-phenethylhepta-3,4-dien-1-yl)-1,3-dioxane (2p).



From **1p** (85 mg, 0.2 mmol) and (1,3-dioxan-2ylethyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above (temperature was changed to rt), compound **2p** (48 mg, 0.14 mmol) was obtained in 72% yield as a pale yellow oil, after purification by flash column chromatography (cyclohexane/EtOAc 90:10).

¹H NMR (300 MHz, CDCl₃) δ 7.31 – 7.22 (m, 2H), 7.22 – 7.13 (m, 3H), 5.18 (qt, *J* = 6.2, 3.1 Hz, 1H), 4.54 (t, *J* = 5.1 Hz, 1H), 4.15 – 4.05 (m, 2H), 3.83 – 3.67 (m, 2H), 2.74 (t, *J* = 7.9 Hz, 2H), 2.51 – 2.41 (m, 2H), 2.32 – 2.01 (m, 10H), 1.79 – 1.68 (m, 2H), 1.38 – 1.29 (m, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 201.0, 142.2, 128.5, 128.3, 125.8, 104.4, 102.0, 91.8, 67.0, 34.6, 34.1, 33.8, 33.4, 29.3, 26.9, 26.0, 15.69. **HRMS** (EI) calculated for C₂₀H₂₈O₂S [M]⁺: 332.1810; Found: 332.1797.

(±)-1-Bromo-3-(octa-2,3-dien-4-yl)benzene (2q).



From **1f** (83 mg, 0.2 mmol) and *n*-butylmagnesium chloride solution in THF (0.22 mmol) following the general procedure described above, compound **2q** (30 mg, 0.11 mmol) was obtained in 57% yield as a pale yellow oil, after purification by flash column chromatography (hexane/Et₂O 98:2).

¹**H NMR** (300 MHz, CDCl₃) δ 7.51 (t, J = 1.8 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.16 (dd, J = 8.3, 7.4 Hz, 1H), 5.49 (qt, J = 6.9, 3.1 Hz, 1H), 2.41 – 2.31 (m, 2H), 1.76 (d, J = 0.7 Hz, 3H), 1.58 – 1.34 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 205.0, 140.3, 129.8, 129.3, 129.2, 124.6, 122.7, 104.3, 89.5, 30.1, 29.6, 22.5, 14.4, 14.1. **HRMS** (EI) calculated for C₁₄H₁₇Br [M]⁺: 264.0514; Found: 264.0478.

(±)-1-(Octa-2,3-dien-4-yl)-4-(trifluoromethyl)benzene (2r).



From **1I** (81 mg, 0.2 mmol) and *n*-butylmagnesium bromide chloride solution in THF (0.22 mmol) following the general procedure described above, compound **2r** (42 mg, 0.17 mmol) was obtained in 83% yield as a pale yellow oil, after purification by flash column chromatography (pentane /Et₂O 98:2).

¹**H NMR** (300 MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 5.52 (qt, J = 6.8, 3.1 Hz, 1H), 2.45 – 2.35 (m, 2H), 1.78 (d, J = 7.0 Hz, 3H), 1.58 – 1.35 (m, 5H), 0.94 (t, J = 7.2 Hz, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 205.6, 141.7, 128.4 (q, $J_{C-F} = 32.4$ Hz), 126.3, 125.3 (q, $J_{C-F} = 3.9$ Hz), 124.5 (q, $J_{C-F} = 270.3$ Hz), 104.5, 89.6, 30.2, 29.6, 22.5, 14.3, 14.1. **HRMS** (EI) calculated for C₁₅H₁₇F₃ [M]⁺: 254.1282; Found: 254.1279.

(±)-1-Bromo-3-(1-phenylhexa-3,4-dien-3-yl)benzene (2s).



From (±)-1f (83 mg, 0.2 mmol) and phenethylmagnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (±)-2s (55 mg, 0.18 mmol) was obtained in 88% yield as a pale yellow oil, after purification by flash column chromatography (hexane/Et₂O 98:2).

¹**H NMR** (300 MHz, CDCl₃) δ 7.52 (t, J = 1.9 Hz, 1H), 7.34 – 7.27 (m, 4H), 7.24 – 7.14 (m, 4H), 5.51 (qt, J = 6.9, 3.1 Hz, 1H), 2.88 – 2.79 (m, 2H), 2.74 – 2.59 (m, 2H), 1.69 (d, J = 7.0 Hz, 3H). ¹³**C**

NMR (76 MHz, CDCl₃) δ 205.1, 142.0, 139.9, 129.9, 129.5, 129.1, 128.6, 128.5, 126.0, 124.6, 122.8, 103.8, 90.3, 34.2, 31.7, 14.3. **HRMS** (EI) calculated for C₁₈H₁₇Br [M]⁺: 312.0514; Found: 312.0485.

(-)-(R)-1-Methoxy-3-(2-methylhexa-3,4-dien-3-yl)benzene (2t).



From (*R*)-1b (75 mg, 0.2 mmol) and phenethylmagnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2t (50 mg, 0.19 mmol) was obtained in 95% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 95:5). From (±)-1b, following the same procedure without SPhos, compound (±)-2t (52 mg, 0.20 mmol) was obtained in 97% yield.

Compound (*R*)-2t was obtained in 96:4 enantiomeric ratio determined by SFC using Chiralpak-IB column [CO₂/MeOH (99:1)], 1 mL/min, τ_{major} = 25.4 min, τ_{minor} = 30.8 min. ¹H **NMR** (300 MHz, CDCl₃) δ 7.26 – 7.08 (m, 7H), 6.96 – 6.87 (m, 2H), 6.68 (ddd, *J* = 8.2, 2.5, 1.1 Hz, 1H), 5.39 (qt, *J* = 6.9, 3.0 Hz, 1H), 3.73 (d, *J* = 1.1 Hz, 3H), 2.77 (dd, *J* = 8.2, 5.8 Hz, 2H), 2.69 – 2.57 (m, 2H), 1.61 (dd, J = 7.1, 1.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 205.0, 159.9, 142.3, 139.1, 129.4, 128.7, 128.4, 125.9, 118.7, 112.1, 111.9,

104.7, 89.7, 55.4, 34.4, 31.9, 14.4. **HRMS** (EI) calculated for $C_{19}H_{20}O$ [M]⁺: 264.1514; Found: 264.1481. [α]²⁵_D= -52.0 (*c* = 1.0, CHCl₃).

(-)-(R)-Octa-5,6-diene-1,5-diyldibenzene (2u).



From (*R*)-1a (75 mg, 0.2 mmol) and (4phenylbutyl)magnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2u (47 mg, 0.18 mmol) was obtained in 90% yield as a pale-yellow oil, after purification by flash column chromatography (hexanes). From (±)-1a, following the same procedure, compound (±)-2u (46 mg, 0.18 mmol) was obtained in 88% yield.

Compound (*R*)-2u was obtained in 98:2 enantiomeric ratio determined by SFC using Chiralpak-ID column [CO₂/MeOH (99:1)], 1 mL/min, τ_{major} = 11.3 min, τ_{minor} = 12.9 min. ¹H NMR, ¹³C NMR and MS data were consistent with literature values.⁵ [α]²⁵_D= - 54.0 (*c* = 1.0, CHCl₃).

(±)-1-Methoxy-4-(2-methylhexa-3,4-dien-3-yl)benzene (2v).



From **1c** (75 mg, 0.2 mmol) and isopropylmagnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound 2v (40 mg, 0.20 mmol) was obtained in 98% yield as a pale-yellow oil, after purification by flash column chromatography (cyclohexane/EtOAc 95:5).

²**v** ¹**H NMR** (300 MHz, CDCl₃) δ 7.38 – 7.28 (m, 2H), 6.91 – 6.83 (m, 2H), 5.47 (qd, J = 6.9, 2.4 Hz, 1H), 3.81 (s, 3H), 2.87 – 2.66 (m, 1H), 1.76 (dd, J = 6.9, 0.7 Hz, 3H), 1.13 (d, J = 5.8 Hz, 3H), 1.10 (d, J = 5.6 Hz, 3H). ¹³**C NMR** (75 MHz, CDCl₃) δ 203.4, 158.4, 129.9, 127.7, 113.9, 112.1, 89.8, 55.4, 28.2, 22.7, 22.3, 14.8. **HRMS** (EI) calculated for C₁₄H₁₈O [M]⁺: 202.1358; Found: 202.1354.

(-)-(R)-1-Methoxy-3-(1-phenylhexa-3,4-dien-3-yl)benzene (2w).



From (*R*)-1b (75 mg, 0.2 mmol) and isopropylmagnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2w (33 mg, 0.16 mmol) was obtained in 82% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 95:5). From (±)-1b, following the same procedure, compound (±)-2w (29 mg, 0.14 mmol) was obtained in 71% yield.

Compound (*R*)-2w was obtained in 97:3 enantiomeric ratio determined by SFC using Chiralpak-IB column [CO₂/MeOH (99.5:0.5)], 0.5 mL/min, τ_{major} = 26.3 min, τ_{minor} = 24.5 min. ¹H NMR (300 MHz, CDCl₃) δ 7.23 (t, *J* = 7.8 Hz, 1H), 7.02 – 6.97 (m, 1H), 6.97 –

6.94 (m, 1H), 6.78 – 6.72 (m, 1H), 5.49 (qd, J = 6.9, 2.3 Hz, 1H), 3.81 (s, 3H), 2.79 (pd, J = 6.7, 2.3 Hz, 1H), 1.76 (d, J = 6.9 Hz, 3H), 1.13 (d, J = 5.3 Hz, 3H), 1.11 (d, J = 5.2 Hz, 3H). ¹³**C** NMR (75 MHz, CDCI3) δ 203.9, 159.8, 139.3, 129.3, 119.2, 112.7, 112.6, 111.6, 90.0, 55.3, 28.1, 22.7, 22.4, 14.6. HRMS (EI) calculated for C₁₄H₁₉O [M+H]⁺: 204.1436; Found: 204.1427. [α]²⁵_D= -47.6 (c = 1.0, CHCI₃)

(-)-(R)-Methyl 4-(2-methylhexa-3,4-dien-3-yl)benzoate (2x).



From (*R*)-1g (79 mg, 0.2 mmol) and isopropylmagnesium bromide solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2x (39 mg, 0.17 mmol) was obtained in 85% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3). From (±)-1g, following the same procedure without SPhos, compound (±)-2x (44 mg, 0.19 mmol) was obtained in 95% yield.

Compound **(***R***)-2x** was obtained in 97:3 enantiomeric ratio determined by SFC using Chiralpak-ID column [CO₂/MeOH (99:1)], 1 mL/min, τ_{major} = 14.4 min, τ_{minor} = 14.0 min.

Using isopropylmagnesium chloride solution in THF (0.22 mmol) compound (*R*)-2x (41 mg, 0.18 mmol) was obtained in 89% yield and 97:3 enantiomeric ratio as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3).

Using isopropylmagnesium chloride solution in Et₂O (0.22 mmol) compound (*R*)-2x (12 mg, 0.05 mmol) was obtained in 26% yield and 90:10 enantiomeric ratio as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3). The low yield could be due to a lower solubility of the starting material in the final CH₂Cl₂/Et₂O solution.

¹**H** NMR (300 MHz, CDCl₃) δ 8.02 – 7.89 (m, 2H), 7.49 – 7.38 (m, 2H), 5.55 (qd, J = 7.0, 2.4 Hz, 1H), 3.90 (s, 3H), 2.82 (septd, J = 6.7, 2.4 Hz, 1H), 1.78 (d, J = 7.0 Hz, 3H), 1.13 (d, J = 6.7 Hz, 3H), 1.11 (d, J = 6.7 Hz, 3H). ¹³**C** NMR (75 MHz, CDCl₃) δ 204.8, 167.2, 142.6, 129.7, 127.9, 126.4, 112.3, 90.6, 52.1, 27.8, 22.6, 22.3, 14.4. HRMS (ESI) calculated for C₁₅H₁₈NaO₂ [M+Na]⁺: 253.1204; Found: 253.1198. [α]²⁵_D= -83.7 (c = 1.0, CHCl₃).

(-)-(R)-1-Bromo-3-(2,2-dimethylhexa-3,4-dien-3-yl)benzene (2y).



From (*R*)-1f (83 mg, 0.2 mmol) and *tert*-butylmagnesium chloride solution in THF (0.22 mmol) following the general procedure described above, compound (*R*)-2y (43 mg, 0.16 mmol) was obtained in 81% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3). From (±)-1f, following the same procedure, compound (±)-2y (38 mg, 0.14 mmol) was obtained in 72% yield.

Compound (*R*)-2y was obtained in 98:2 enantiomeric ratio determined by GC on a Chirasil Dex-CB column (60 °C, hold 3 min, 60 \rightarrow 120 °C @ 10 °C/min, hold 2 min, then \rightarrow 160 °C @ 0.5 °C/min, then \rightarrow 180 °C @ 10 °C/min; flow rate 1.0 mL/min.). τ_{major} = 27.6 min, τ_{minor} = 27.9 min. ¹H NMR (300 MHz, CDCl₃) δ 7.52 – 7.30 (m, 2H), 7.22 – 7.07 (m, 2H), 5.20 (q, *J* = 6.9 Hz, 1H), 1.69 (d, *J* = 6.9 Hz, 3H), 1.12 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 202.6, 140.6, 132.4, 129.5, 129.3, 128.1, 121.8, 114.1, 86.8, 34.3, 30.0, 14.8. HRMS (EI) calculated for C₁₄H₁₇Br [M]⁺: 264.0514; Found: 264.0506. [α]²⁵_D= -22.3 (*c* = 1.0, CHCl₃).

(S)-(3-isopropylhexa-3,4-dien-1-yl)benzene (2z).



From (*R*)-1z (73 mg, 0.2 mmol) and isopropylmagnesium chloride solution in THF (0.22 mmol) following the general procedure described above, compound (*S*)-2z (35 mg, 0.18 mmol) was obtained in 88% yield as a pale yellow oil, after purification by flash column chromatography (pentane/Et₂O 97:3). From (±)-1z, following the same procedure, compound (±)-2z (33 mg, 0.17 mmol) was obtained in 83% yield.

Compound (*R*)-2z was obtained in 98:2 enantiomeric ratio determined by GC on a Chirasil Dex-CB column (60 °C, hold 3 min, then $60 \rightarrow 80$ °C @ 10 °C/min, hold 2 min, then $\rightarrow 140$ °C @ 0.5 °C/min, then $\rightarrow 180$ °C @ 10 °C/min, hold 3 min; flow rate 1.0 mL/min.). τ_{major} = 68.5 min, τ_{minor} = 70.1 min. ¹H NMR (300 MHz, CDCl₃) δ 7.24 – 7.04 (m, 5H), 5.14 – 4.98 (m, 1H), 2.70 – 2.58 (m, 2H), 2.23 – 2.12 (m, 2H), 2.10 – 1.92 (m, 1H), 1.52 (d, J = 6.8 Hz, 3H), 0.93 (dd, J = 6.8, 1.5 Hz, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 200.9, 142.8, 128.6, 128.3, 125.8, 110.0, 88.3, 34.5, 32.7, 31.4, 22.0, 21.9, 15.2. HRMS (EI) calculated for C₁₅H₂₀ [M]⁺: 200.1565; Found: 200.1573. [α]²⁵_D= -8.4 (*c* = 1.0, CHCl₃).

6 ASSIGNMENT OF ABSOLUTE CONFIGURATION

The absolute configuration was stablished for compound (*R*)-**2u**, by comparison of the sign of the optical rotation with that reported in the literature.⁴ The absolute configuration of (*R*)-**2u** reveals an *anti* $S_N 2$ ' attack of the *in situ* formed cuprate to the ammonium salt. We assumed the same stereochemical outcome for all the enantiomerically enriched compounds prepared.



7 NMR SPECTRA











S22









































8 SFC CROMATOGRAMS



Peak	RetTime	Туре	Width	Area	Height	Area	
#	[min]		[min]	[mAU*s]	[mAU]	%	
1	6.408	MM	0.3209	20.14356	1.04634	1.4418	
2	11.248	MM	0.3226	1376.94812	71.13525	98.5582	

S37





Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	90
1	12.901	MM	0.2863	9354.37109	544.54041	98.1767
2	14.143	MM	0.3158	173.72585	9.16906	1.8233











S41



Реак	Retiime	туре	wiath	Area	Height	Area	
#	[min]		[min]	[mAU*s]	[mAU]	%	
1	27.740	MM	0.1686	211.90648	20.94443	1.6059	
2	28.348	MM	0.5587	1.29838e4	387.30658	98.3941	





reak	Veritille	Type	withtin	Area	nergit	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	11.270	MM	0.3278	4.92720e4	2504.91699	97.5937
2	12.926	MM	0.4479	1214.87415	45.20641	2.4063











Peak	Start	End	RT	Area	Area %	Height
1	27,526	27,812	27,617	57815039,65	99,01	7188815,72
2	27,823	28,195	27,909	58391186,5	100	5013215,34



Peak	Start	End	RT	Area	Area %	Height
1	27,502	27,94	27,6	125290537,7	100	13710111,58
2	27,954	28,13	28	1953058,44	1,56	272926,73



Peak	Start	End	RT	Area	Area %	Height
1	68,214	69,124	68,312	36503417,47	95,12	1180333,3
2	69,136	70,686	69,239	38378069,77	100	785301,23



Peak	Start	End	RT	Area	Area %	Height
1	68,426	70,034	68,483	46915341,96	100	1154087,64
2	70,086	70,715	70,091	799440,78	1,7	38877,59

9 REFERENCES

- ¹ Knochel, P. *Synthesis-Stuttgart*, **2006**, *5*, 890.
 ² Guisán-Ceinos, M.; Martín-Heras, V.; Tortosa, M. *J. Am. Chem. Soc.* **2017**, *139*, 8448.
 ³ Jiang, B.; Chen, Z.; Xiong, W. *Chem. Comm.* **2002**, *14*, 1524
 ⁴ Soler-Yanes, R.; Arribas-Álvarez, I.; Guisán-Ceinos, M.; Buñuel, E.; Cárdenas, D. J. *Chem. Eur. J.* **2017**, *23*, 1584.
 ⁵ Uehling, M.R.; Marionni, S.T.; Lalic, G. *Org. Lett.*, **2012**, *14*, 362.